Apart from steroidal mechanisms, inhibition of the receptor tyrosine kinase IGFR was shown to downregulate syndecan-4 levels in estrogen receptor-positive breast cancer cells via an endocytic mechanism [67]. This evidence concerns the gene SDC4 and breast cancer.